Researchers demonstrated that combined SIRPα-Fc and CQ treatment interrupted the CD47/SIRPα axis and disrupted the protective autophagy in tumor cells, enhanced phagocytosis of macrophages, and then activated CD8+ T cell-mediated anti-tumor immune (111). Here, SIRPA is linked to neoplasm.